NASDAQ:OCUL - Ocular Therapeutix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.01 -0.16 (-2.59 %) (As of 10/22/2018 04:00 PM ET)Previous Close$6.17Today's Range$5.85 - $6.1952-Week Range$3.30 - $8.28Volume408,200 shsAverage Volume406,730 shsMarket Capitalization$238.11 millionP/E Ratio-2.73Dividend YieldN/ABeta1.21 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts. Receive OCUL News and Ratings via Email Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OCUL CUSIPN/A Webwww.ocutx.com Phone781-357-4000 Debt Debt-to-Equity Ratio0.21 Current Ratio4.92 Quick Ratio4.91 Price-To-Earnings Trailing P/E Ratio-2.73 Forward P/E Ratio-3.93 P/E GrowthN/A Sales & Book Value Annual Sales$1.92 million Price / Sales120.79 Cash FlowN/A Price / CashN/A Book Value$0.72 per share Price / Book8.35 Profitability EPS (Most Recent Fiscal Year)($2.20) Net Income$-63,380,000.00 Net Margins-2,814.72% Return on Equity-143.32% Return on Assets-84.27% Miscellaneous Employees119 Outstanding Shares38,590,000Market Cap$238.11 million Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions What is Ocular Therapeutix's stock symbol? Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL." How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.37). The biopharmaceutical company had revenue of $0.65 million for the quarter, compared to analysts' expectations of $0.35 million. Ocular Therapeutix had a negative net margin of 2,814.72% and a negative return on equity of 143.32%. View Ocular Therapeutix's Earnings History. When is Ocular Therapeutix's next earnings date? Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Ocular Therapeutix. What price target have analysts set for OCUL? 6 equities research analysts have issued 1 year price objectives for Ocular Therapeutix's shares. Their forecasts range from $9.00 to $22.00. On average, they expect Ocular Therapeutix's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 120.5% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix. What is the consensus analysts' recommendation for Ocular Therapeutix? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix. What are Wall Street analysts saying about Ocular Therapeutix stock? Here are some recent quotes from research analysts about Ocular Therapeutix stock: 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (8/15/2018) 2. Cantor Fitzgerald analysts commented, "We rate Ocular Therapeutix (OCUL) 12-month price target of $22 per share. Ocular focuses on a platform of sustained drug-delivered therapies for the treatment of ocular diseases and conditions. Ocular’s lead development product, DEXTENZA, is an intracanalicular dexamethasone insert therapy for the treatment of post-surgical ocular pain. We believe Ocular could receive FDA approval in 2018. Valuation Summary We arrive at our 12-month price target of $22/share by assessing the after-tax, risk- adjusted NPV of future cash flows from DEXTENZA." (7/19/2018) 3. HC Wainwright analysts commented, "We continue to believe that Dextenza has the potential to obtain regulatory approval in the U.S. by the end of 2018 and start generating revenue around mid-2019. The company plans to apply for a pass-through reimbursement status (C code) for Dextenza. With bundled pricing of cataract surgery, Dextenza should be priced above $480 per dose according to CMS guidelines, in our view. In the wake of this update, we reiterate our Buy rating and $10 price target." (6/21/2018) 4. BTIG Research analysts commented, "On Thursday, before market open, the management team of Ocular Therapeutix hosted their 4Q17 earnings call. We think the updates provided on the call were in line with expectations. The company expects to resubmit the Dextenza NDA during 1H2018, with an FDA decision likely by YE2018. Key leadership positions have also been filled including the hiring of experienced quality and regulatory personnel, which we think could further provide additional investor confidence moving forward. We reiterate our Buy rating and $9 Price Target." (3/11/2018) Who are some of Ocular Therapeutix's key competitors? Some companies that are related to Ocular Therapeutix include Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), Lexicon Pharmaceuticals (LXRX), Revance Therapeutics (RVNC), Akorn (AKRX), Eagle Pharmaceuticals (EGRX), Aptinyx (APTX), Athenex (ATNX), Radius Health (RDUS), Alder Biopharmaceuticals (ALDR), Amphastar Pharmaceuticals (AMPH), Viking Therapeutics (VKTX), Deciphera Pharmaceuticals (DCPH), MacroGenics (MGNX) and AMAG Pharmaceuticals (AMAG). Who are Ocular Therapeutix's key executives? Ocular Therapeutix's management team includes the folowing people: Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 51)Mr. Antony Mattessich, Pres, CEO & Director (Age 51)Mr. Donald Notman Jr., Chief Financial OfficerDr. Michael H. Goldstein, Chief Medical Officer (Age 51)Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 56) Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Deltec Asset Management LLC (1.61%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Institutional Ownership Trends for Ocular Therapeutix. Which institutional investors are buying Ocular Therapeutix stock? OCUL stock was bought by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Insider Buying and Selling for Ocular Therapeutix. How do I buy shares of Ocular Therapeutix? Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ocular Therapeutix's stock price today? One share of OCUL stock can currently be purchased for approximately $6.01. How big of a company is Ocular Therapeutix? Ocular Therapeutix has a market capitalization of $238.11 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe. What is Ocular Therapeutix's official website? The official website for Ocular Therapeutix is http://www.ocutx.com. How can I contact Ocular Therapeutix? Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected] MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 264 (Vote Outperform)Underperform Votes: 161 (Vote Underperform)Total Votes: 425MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/22/2018 by MarketBeat.com StaffFeatured Article: What strategies should day traders use to execute a trade?